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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of pancreatic cancer
Incidence
. The crude incidence and mortality of pancreatic cancer in the
European Union is about 11/100 000 per year. In around 5%
of patients some genetic basis for the disease can be found.
Diagnosis
. Pathological diagnosis should be made according to the
World Health Organisation classification from a biopsy or
fine needle aspiration. Ductal adenocarcinomas constitute
95% of the epithelial tumors.
Staging and risk assessment
. Staging consists of complete history and physical examin-
ation, blood counts, liver enzymes, chest X-ray, imaging of
the abdomen by sonography and CT scan or magnetic
resonance, and possibly by endosonography.
. Patients with pancreatic cancer may be staged according to
the TNM system and can be grouped as in Table 1.
. However, the distinction of whether or not a tumor remains
resectable is not well reflected in the TNM system and
survival is more dependent on age than on TNM stage, as
demonstrated by the wide range of survival figures given for
each stage.
. Evaluation of resectability often requires surgery, preferably
by staging laparoscopy to exclude clinically occult intra-
abdominal and lymph node metastases.
. To be resectable, tumors must show no evidence of extra-
pancreatic disease or direct tumor extension to the celiac
axis and superior mesenteric artery nor evidence of non-
obstructive invasion of the superior mesenteric-portal vein
confluence.
. Less than 20% of all patients have resectable disease.
Treatment of resectable tumors
. Complete surgical resection is the only potentially curative
treatment available. However, five-year overall survival is
only 10–20%. Long-term survival in N+ tumors is rare.
. Preoperative or postoperative chemotherapy with or without
radiotherapy remains controversial.
Treatment of locally advanced or metastatic
disease
. Optimal symptomatic treatment has a prime role in the man-
agement of metastastic disease. This may require stenting or
bypass surgery for obstructive jaundice or gastric outlet
obstruction.
. The role of chemotherapy is limited. Gemcitabine has been
associated with a small survival benefit compared with
bolus 5-fluorouracil [II, B].
Response evaluation
. Objective response evaluation by the initial radiographic
test may not be necessary for adequate patient management.
Evaluation of response should be symptom-driven.
Follow-up
. Due to the limited effectiveness of treatments follow up
after complete resection should be restricted to history and
physical examination.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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Table 1.
Stage Primary
tumor
Lymph
nodes
Distant
mets
5-year
survival
Stage 0 Tis N0 M0 –
Stage I T1-2 N0 M0 5–35%
Stage II T3 N0 M0 2–15%
Stage III T1-3 N1 M0 2–15%
Stage IVA T4 Any N M0 1–5%
Stage IVB Any T Any N M1 <1%
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